Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 12/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.33 |
| ▸ | TNF | P01375 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6739645 | 0.87 | HRH3 (0.40) | HRH3KDM4E | |
| SCHEMBL7662241 | 0.80 | HRH3 (0.42) | HRH3KDM4E | |
| SCHEMBL6737633 | 0.79 | HRH3 (0.41) | KAT2BHRH3KDM4ETNF | |
| SCHEMBL7657040 | 0.79 | HRH3 (0.39) | HRH3 | |
| SCHEMBL6739327 | 0.78 | HRH3 (0.41) | HRH3KDM4EMEN1KMT2A | |
| SCHEMBL6735998 | 0.75 | KDM4E (0.46) | KDM4EMEN1KMT2A | |
| SCHEMBL6737938 | 0.74 | HRH3 (0.35) | HRH3KDM4E | |
| SCHEMBL6734382 | 0.74 | HRH3 (0.40) | HRH3KDM4E | |
| SCHEMBL6739873 | 0.73 | HRH3 (0.35) | HRH3KDM4E | |
| SCHEMBL6735891 | 0.73 | HRH3 (0.42) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127507-A1 | Imidazolidine compounds | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2004-07-01 | — | — | US | disclosed |
| US-20040122026-A1 | Imidazolidine compounds | MILLENNIUM PHARMACEUTICALS, INC. | 2004-06-24 | — | — | US | disclosed |
| US-20030225288-A1 | Imidazolidine compounds | MILLENNIUM PHARMACEUTICALS, INC. | 2003-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127507-A1 | Imidazolidine compounds | IRAK1, IRAK4, IRAK2 | KAT2B 1999/4885HRH3 530/4885KDM4E 4423/4885 |
| US-20030225288-A1 | Imidazolidine compounds | IRAK1, IRAK4, IRAK2 | KAT2B 1999/4885HRH3 530/4885KDM4E 4423/4885 |
| US-20040122026-A1 | Imidazolidine compounds | IRAK1, IRAK4, IRAK2 | KAT2B 1999/4885HRH3 530/4885KDM4E 4423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.